Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

WDR5 0103

A WD repeat-containing protein 5 (WDR5) antagonist
Catalog #: B1125
SKU-Size Size Price Qty
B1125-10 10 mg
$135.00
B1125-50 50 mg
$535.00
More Sizes Get Quote

Product Details

Alternate Name 3-[(3-Methoxybenzoyl)amino]-4-(4-methyl-1-piperazinyl)benzoic acid methyl ester
Appearance White Solid
CAS # 890190-22-4
Molecular Formula C₂₁H₂₅N₃O₄
Molecular Weight 383.44
Purity ≥98% by HPLC
Solubility DMSO (>35 mg/ml)
SMILES CN1CCN(CC1)C2=C(C=C(C=C2)C(=O)OC)NC(=O)C3=CC(=CC=C3)OC
InChi 1S/C21H25N3O4/c1-23-9-11-24(12-10-23)19-8-7-16(21(26)28-3)14-18(19)22-20(25)15-5-4-6-17(13-15)27-2/h4-8,13-14H,9-12H2,1-3H3,(H,22,25)
InChi Key ZPLBXOVTSNRBFB-UHFFFAOYSA-N
PubChem CID 6457069
Handling Protect from air and light
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

WDR5-0103 is a small molecule that binds a peptide-binding pocket on WDR5 (Kd = 450 nM). It inhibits the catalytic activity of MLL core complex in in vitro experiments with IC₅₀ of 39 µM. WDR5 is a component of mixed lineage leukemia (MLL) that targets histone-3 and in vitro data shows interaction of WDR5-0103 with MLL inhibits MLL core complex methyltransferase activity. However WDR5-0103 has no effect on other methyltransferases.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.